USD10
GILD Shares
About Gilead SciencesGilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
USD10
GILD Shares
About Gilead SciencesGilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 26 at 1:30 PM GMT+0
MARKET CAP
$171.12B
OPEN PRICE
Not enough data
LOW (1Y)
$93.37
HIGH (1Y)
$157.29
LOW (24H)
$137.92
HIGH (24H)
$140.42
VOLUME (24H)
$1.52K
99.98%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $139.85 | |
1 Week | $141.46 | |
1 Month | $145.08 | |
1 Year | $111.16 |